Pasithea therapeutics announces opening of european clinical trial sites and completes initial dosing of cohort 4

-- interim data from cohort 4 expected q1 2025 -- miami, jan. 14, 2025 (globe newswire) -- pasithea therapeutics corp. (nasdaq: ktta) (“pasithea” or the “company”), a clinical-stage biotechnology company developing pas-004, a next-generation macrocyclic mek inhibitor, for the treatment of neurofibromatosis type 1 (nf1) and other cancer indications, today announced it has opened three clinical trial sites in eastern europe. these sites in romania and bulgaria are actively recruiting patients along with the four open sites in the united states, for pasithea's pas-004 phase 1 trial.
KTTA Ratings Summary
KTTA Quant Ranking